Familiarize yourself with KADCYLA® (ado-trastuzumab emtansine) preparation and storage in HER2+ early breast cancer. See Full Safety and Boxed Warnings for more information.
Kadcyla: Package Insert
Questions to Ask About KADCYLA® (ado-trastuzumab emtansine) for EBC
WO2015164665A1 - Methods of treating early breast cancer with
Conjugated Monoclonal Antibodies Market Share, Trends, Industry
Kadcyla (ado-trastuzumab emtansine) Cancer Medication - Cancer Health
KADCYLA® (ado-trastuzumab emtansine) in HER2+ Early Breast Cancer
Trastuzumab (Intravenous) Including Biosimilars of Trastuzumab
Clinical Trial Information for KADCYLA® (ado-trastuzumab emtansine
Clinical Trial Results in EBC KADCYLA® (ado-trastuzumab emtansine)
Antibody-Drug Conjugates in the Treatment of Breast Cancer
/i.s3.glbimg.com/v1/AUTH_b58693ed41d04a39826739159bf600a0/internal_photos/bs/2023/B/h/Nmqin0SKqJeguaF8WjAQ/2023-fifa-womens-world-cup.png)
